thrombolytic


Also found in: Thesaurus, Medical, Wikipedia.

throm·bol·y·sis

 (thrŏm-bŏl′ĭ-sĭs)
n. pl. throm·bol·y·ses (-sēz)
Dissolution or destruction of a thrombus.

throm′bo·lyt′ic (-bə-lĭt′ĭk) adj.

thrombolytic

(ˌθrɒmbəˈlɪtɪk)
adj
(Medicine) causing the break-up of a blood clot
n
(Pharmacology) a thrombolytic drug
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.thrombolytic - a kind of pharmaceutical that can break up clots blocking the flow of blood to the heart muscle
pharmaceutic, pharmaceutical - drug or medicine that is prepared or dispensed in pharmacies and used in medical treatment
Activase, tissue plasminogen activator - a thrombolytic agent (trade name Activase) that causes fibrinolysis at the site of a blood clot; used in treating acute myocardial infarction
Translations

throm·bo·lyt·ic

a. trombolítico-a, rel. a un trombo o que causa la disolución de éste.

thrombolytic

adj & n trombolítico
References in periodicals archive ?
Thrombolytic Science LLC, a clinical stage vascular health and biotechnology company, has completed a Phase 1 clinical trial of TS01, a new-generation clot-dissolving therapy, it was reported yesterday.
1] Intervention with thrombolytic agents in AMI is an effective means of limiting myocardial damage.
4,5 Numerous studies had confirmed that early intravenous thrombolysis was an effective method to treat acute ischemic stroke (AIS), and the earlier the thrombolytic therapy, the greater the likely benefits for the patients, and the risk of bleeding transformation would also be reduced.
Subsequently, they were treated with oral thrombolytic therapy (Lumbrokinase) for 12 weeks and all the patients had complete resolution of thrombus at three months follow-up and made a full recovery.
In case of stroke, new thrombolytic agent is needed to be isolated from the medicinal plants.
The Clot Specific Streptokinase (CSSK), a novel patented thrombolytic biopharmaceutical therapeutic protein drug licensed from the CSIR-Institute of Microbial Technology (CSIR-IMTECH), Chandigarh, a constituent institute of the Council of Scientific and Industrial Research (CSIR), has received permission from the Drugs Controller General of India (DGCI) to conduct Phase-2 human clinical trial to test the efficacy of CSSK in the patients of heart attack, a condition known as Acute Myocardial Infarction.
Thrombolytic drugs act rapidly to dissolve unwanted blood clots (thrombi) in blood vessels.
Thrombolytic therapy promotes rapid disintegration of the thrombus or embolus in many conditions, such as myocardial infarction (MI) (Kunadian & Gibson, 2012), acute stroke (Feske, 2012), pulmonary embolism (Stein & Matta, 2012), deep vein thrombosis (DVT) (Dasari, Pappi, & Hennebry, 2012), venous thromboembolism (Findlay, Keogh, & Cooper, 2010), frostbite injury (Gross & Moore, 2012), and central venous catheter occlusion (Baskin et al.
Thrombolytic therapy has become the gold standard in the treatment of acute myocardial infarction (MI), in the absence of contraindications (1,2).
According to the last guidelines of the European Stroke Initiative (EUSI) and American Stroke Association a thrombolytic therapy (TT) performed within treatment window is a promising method for early recanalization of the occluded vessel in acute stroke patients (Suslina et al, 1997; AHA/ASA Scientific Statement Guidelines for the Early Management of Patients with Ischemic Stroke 2005 Guidelines Update, 2005; European Stroke Initiative Recommendations for stroke Management--Update 2003).
The application of a thrombolytic agent to a clotted blood or bone marrow specimen is a possible resolution to this recurrent problem.